ImmunoCellular Therapeutics (IMUC) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Join SI Premium – FREE
ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20).
For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
